UPCC 35423 Fitness-adapted, pembrolizumab-based therapy for untreated classical Hodgkin lymphoma patients 60 years of age and above (cHL 001)
Enrolling By Invitation
99 years and younger
All
Phase
N/A
1 Location
Brief description of study
Please refer to Protocol Section 3.1 (Primary Objectives, Endpoints & Hypotheses). Please refer to Protocol Section 3.1 Primary Objectives, Endpoints & Hypotheses. Please refer to Protocol Section 3.2 (Secondary Objectives and Endpoints).
Eligibility of study
You may be eligible for this study if you meet the following criteria:
-
Conditions:
Medical Research
-
Age: - 99 Years
-
Gender: All
TBD
Updated on
08 May 2024.
Study ID: 854828
If you need assistance finding a non-cancer clinical research study or if you have any questions, please email psom-ocr@pobox.upenn.edu
For cancer trials contact EmergingMed: 1-855-216-0098 or PennCancerTrials@emergingmend.com
